Medically reviewed by a licensed healthcare professional. Last updated April 2026.

Key Takeaways

  • Lilly's label requires Zepbound to be stopped at least 2 months before a planned pregnancy. Tirzepatide's half-life is about 5 days; the 2-month window is a hard washout, not a guideline.
  • Oral birth control may be less effective during the first 4 weeks of Zepbound and during each dose escalation. Backup contraception (barrier or non-oral) is the safest play during these windows.
  • Animal studies show fetal harm at clinically relevant doses. There is no human trial data on tirzepatide in pregnancy and there will not be one.
  • "Zepbound babies" are a real and growing phenomenon. The metabolic restoration that comes with weight loss can reactivate fertility, especially in patients with PCOS, obesity-related anovulation, or peri-menopausal cycles.
  • If you find out you're pregnant on Zepbound, stop immediately, call your OB the same day, and enroll in the Lilly pregnancy registry. Most outcomes after early discontinuation are still healthy ones.

Pregnancy planning on a GLP-1 is one of those conversations most patients never have with their prescriber, and the gap shows up later as either a frustrated couple trying to time a conception around a 2-month medication washout or, less commonly, a positive pregnancy test that nobody saw coming. This is a guide for both situations, plus the contraception detail in the middle that almost nobody is told about.

For the broader picture across all GLP-1s, see our Ozempic and Wegovy pregnancy safety post. This one is Zepbound-specific because tirzepatide's label, mechanism, and washout math are different enough to deserve their own coverage.

What Lilly's label actually says

The Zepbound prescribing information is direct on the pregnancy question. It instructs patients to discontinue Zepbound at least 2 months before a planned pregnancy. It also states that the medication is not recommended during pregnancy due to potential fetal harm based on animal studies.

The animal data is what's driving the caution. In rats, tirzepatide caused decreased fetal body weight and increased malformations at exposures comparable to or below the maximum recommended human dose. In rabbits, similar effects were observed at lower exposures. Lilly cannot run a human pregnancy trial on a drug with that pre-clinical signal, so the precautionary stance in the label is what we have to work with.

What we do not have: a clinical trial in pregnant humans showing harm. There never will be one. The pregnancy registry, which collects outcomes from accidental exposures, is how the next generation of guidance will eventually be informed. If you find yourself enrolled, your data is genuinely contributing to a knowledge gap.

The 2-month washout, explained

Tirzepatide has a half-life of approximately 5 days. By standard pharmacokinetic math, a drug clears to undetectable levels after about 5 half-lives, which is roughly 25 days. The 2-month window adds margin for:

  • Individual variation in metabolism (heavier patients clear more slowly)
  • Tissue redistribution (small amounts can persist beyond plasma clearance)
  • Cycle timing safety (2 months covers the full ovulation cycle that produces the egg you'd conceive with)

If you're trying to conceive, the practical implication is that your last Zepbound dose should be at least 8 weeks before the start of the menstrual cycle in which you'd ovulate the egg you want fertilized. Most patients do better timing this around their cycle than around a calendar.

There's a corollary worth flagging: the appetite suppression and metabolic effects of Zepbound do not stop the day you take your last injection. Patients often experience meaningful continued effect for 2 to 4 weeks after the last dose as the drug clears. The dietary and exercise habits you build during this transition often determine whether weight comes back during the conception window. We covered the broader maintenance question in our post on stopping GLP-1s and weight regain.

The contraception interaction nobody talks about

Here's the under-discussed part. Tirzepatide slows gastric emptying as part of its mechanism. That same effect can reduce the absorption of oral medications taken alongside it, including combined oral contraceptives.

Lilly's label is explicit: when starting Zepbound, and after each dose escalation, patients on oral contraceptives should either:

  1. Switch to a non-oral contraceptive method (IUD, implant, hormonal injection, vaginal ring), or
  2. Add a barrier method (condoms) for 4 weeks after starting and 4 weeks after each dose increase

This is a real and recurring issue. Patients start Zepbound, continue their oral pill, get a partial reduction in pill efficacy during the slowest gastric emptying window, and end up surprised. The 4-week buffer after each dose escalation is the part most clinicians forget to mention because the patient is already past the "starting" conversation.

If you're on combined oral contraception and on Zepbound, talk to your prescriber about either switching to a method that bypasses oral absorption entirely, or building the barrier-method backup into your titration timeline.

"Zepbound babies" are real

The "Ozempic babies" stories that hit the news in 2024 had a specific mechanism behind them, and that same mechanism applies to Zepbound. Two effects compound:

Restored ovulation in patients with PCOS. Polycystic ovary syndrome is the most common cause of anovulatory infertility in women. Weight loss and improved insulin sensitivity can restore normal ovulation in a meaningful share of PCOS patients. If a patient with prior PCOS-related anovulation drops 15% body weight and starts ovulating regularly, the contraception conversation she had with her PCP three years ago when nothing was working is no longer accurate.

Improved metabolic-hormonal axis. Obesity itself can suppress ovulation through leptin signaling and insulin resistance. Reversing those metabolic changes can restart cycles in patients whose previous prescriber treated them as effectively infertile.

Combined with the oral contraceptive interaction above, the Zepbound population includes a meaningful subset of patients who are simultaneously (a) more fertile than they were six months ago and (b) on a less effective contraceptive than they realize. The result is the unplanned pregnancy uptick that's been showing up across GLP-1 telehealth registries.

This is not a reason to avoid Zepbound. It is a reason to have a contraception conversation with your prescriber that goes beyond "are you on something."

If you find out you're pregnant on Zepbound

The right sequence:

  1. Stop Zepbound immediately. Do not take the next scheduled dose. The drug is already in your system, but compounding additional exposure makes it worse.
  2. Call your OB/GYN the same day. Earlier prenatal contact is better when there's a known exposure to manage.
  3. Call your Zepbound prescriber. They need to know the medication is being discontinued and why, and they may need to manage your ongoing weight and metabolic care without GLP-1 support.
  4. Enroll in the Lilly pregnancy registry at 1-800-545-5979. The registry collects anonymized outcome data from accidental exposures and is how this knowledge gap will eventually close.
  5. Continue your prenatal vitamins, folic acid, and any non-Zepbound medications your OB clears. The metabolic transition off Zepbound can be uncomfortable; a supportive OB and a clear nutrition plan matter more than usual during this window.

The animal data is concerning, but it is not deterministic. Many patients with early-pregnancy Zepbound exposure go on to have healthy term outcomes. The registry will eventually quantify how many. In the meantime, "stop now and follow your OB's plan" is the right move every time.

Breastfeeding

There are no controlled human studies on tirzepatide in breast milk. Animal studies have shown the drug is excreted in rat milk. The clinical default is to avoid Zepbound while breastfeeding until better data is available.

If you delivered while not on Zepbound and are considering restarting after birth, the conventional advice is to choose either Zepbound or breastfeeding, not both. Some patients delay restarting until weaning; others use the lactation period to lock in nutrition and habit changes that hold weight without pharmacotherapy. Talk to both your OB and your obesity medicine prescriber about timing.

The bigger picture

Zepbound is a powerful drug. Powerful drugs come with powerful caveats, and the pregnancy and contraception parts of the Zepbound conversation are some of the least-communicated. If you're considering Zepbound and you're in a population where pregnancy is even a remote possibility (premenopausal, sexually active, partnered or considering it), the contraception conversation is part of the prescription, not a separate one.

If you want to find a clinic that takes the full prescription seriously, take our provider-matching quiz. The directory filters for clinics whose intake process includes a real fertility and contraception conversation, not a checkbox.

Sources

  1. Zepbound (tirzepatide) Prescribing Information, Eli Lilly
  2. Lilly Pregnancy Exposure Registry information
  3. Tirzepatide pharmacokinetics, Clinical Pharmacokinetics 2022
  4. SURMOUNT-1 trial results, NEJM 2022
  5. GLP-1 receptor agonists and oral contraceptive efficacy, Endocrine Society 2024
  6. PCOS and obesity: weight loss as first-line management, ACOG